Compounder

Usana Health Sciences Inc

1 位超级投资者持有 Usana Health Sciences Inc(USNA)。

仅供教育与信息参考,不构成投资建议。13F 持仓为机构自行申报,可能滞后最多 45 天。

本季动向1 家减仓

估值 · 地基层

Earnings Power & Asset Floor
Two intrinsic-value methods and a tangible asset floor — deterministic, not price forecasts or recommendations.
Margin of safetyPrice sits below both methods' value estimate.
margin of safety
fair value
above fair value
$20
cheaper$37$70 value estimatepricier

Usana Health Sciences Inc (USNA): Two methods value the business — a conservative owner-earnings DCF and a growth-credited Greenwald estimate, $37–$70 / sh. Today’s price sits below both (price $20 as of 2026-06-25).

Model cautions

  • Owner-earnings yield diverges sharply from the 10-year Treasury (over 300 bps).
  • The two methods' midpoints differ materially — growth assumptions warrant review (over 20%).

An observation from two valuation methods — not investment advice, not a buy/sell signal, and not a price target.

Price as of 2026-06-25 · yahoo · DGS10 4.4% @ 2026-06-24.

Method & numbers

Owner-earnings DCF $36.77 – $53.21 · Greenwald $70.36 – $70.36 (neutral $70.36) · zero-growth base $70.36 · reproduction $15.92

Moat Franchise (moat) · terminal value 44% of present value · owner-earnings yield 19% vs 10Y 4.4%.

Graham earnings-power value (normalized NOPAT)$58.00 – $70.36 / sh

Normalized NOPAT = average operating margin over the years shown × latest-year revenue × (1 − normalized tax); then + D&A − maintenance capex (write A). Unlevered (pre-interest, attributable to all capital). Capitalized at the 8–10% rate band (read as a WACC proxy). Enterprise → equity bridge applied: + cash − total debt.

Years: 2026, 2025, 2024, 2023, 2022

v1 simplifications: Maintenance capex (degraded) deducted in full cash (write A): EPV = (NOPAT + D&A − maintenance capex) / WACC; no tax shield on the capex term. Maintenance-capex methods diverge by 275% (> 50%); estimate is degraded. Share-based compensation is left as a real expense (not added back).

Buffett owner-earnings value$36.77 – $45.96 / sh

Owner earnings = average net income + average D&A − maintenance capex (zero-growth floor; no ΔNWC). Levered (starts from net income, already after interest — an equity-holder stream). Capitalized at the 8–10% rate band (read as a cost-of-equity proxy). No enterprise→equity bridge: the capitalized result is already equity value (subtracting debt would double-count interest).

Years: 2026, 2025, 2024, 2023, 2022

v1 simplifications: Owner earnings = net income + D&A − maintenance capex (degraded); the working-capital change is excluded (maintenance ΔNWC ≈ 0; growth ΔNWC is carried in growth value, not double-counted). One-time items are not separately normalized (multi-year averaging smooths them partially). Share-based compensation is left as a real expense (not added back); see the SBC/OE disclosure. Capitalized at the same 8–10% band as a cost-of-equity proxy (theoretically the cost of equity is higher; v2 simplification, v3 to refine).

Reproduction value = tangible net assets $261.99M + capitalized R&D $33.66M (FY 2026, 2025, 2024, 2023, 2022) = $15.92 / sh. Reproduction value = tangible net assets (equity − goodwill − intangibles) + capitalized R&D (5y straight-line), ÷ diluted shares.

Moat reading: Franchise test compares earnings power (EPV) against reproduction value (tangible net assets + capitalized R&D). EPV well above reproduction value signals a moat; near it, a commodity; below it, value destruction. A directional reading, not a verdict.

Growth value: if the moat holds for 10 yr at ROIIC ≈ -109%, $0.00–$0.00 / sh (neutral $0.00). Conservative, not a forecast.

Window FY 2026, 2025, 2024, 2023, 2022 · discount band 8%10% · normalized tax 21% (Average effective tax rate over 5 year(s), capped at the statutory 21%.) · diluted shares.

Owner-earnings DCF: growth g₁ 0% (history declining → capped at 0) · OE FY 2026, 2025, 2024, 2023, 2022 · Discount band: 6.91%–10.00% (DGS10 +2.5% to a 10% strict end, as of 2026-06-24). No enterprise→equity bridge: owner earnings already flow to shareholders (post-interest), so no net cash is added and no debt subtracted — matching the engine owner-earnings lamp. Two-method midpoint gap 47%.

持有该证券的超级投资者

  • 市值$19.4M权重(上季→本季)0.1% 0.1%

持有概览

Usana Health Sciences Inc(USNA)被 Compounder 追踪的 1 位超级投资者持有,合计申报市值 $19.4M。仓位最大的是 Richard Pzena,占其组合 0.1%。

最近一个季度,追踪范围内有 0 位新建 USNA 仓位,0 位加仓,1 位减仓,0 位清仓。

以上持有人数与市值来自最新的 SEC Form 13F 申报,截至 2026-03-31 季度。来源:SEC EDGAR。13F 仅涵盖美股多头持仓,且可能滞后实际组合最多 45 天,因此这是已披露的多头持有情况,并非完整全貌。

持有人趋势

近 8 季持有该证券的超级投资者:1 → 1 家。

早期季度持有人数可能因数据回填偏低,斜率仅供参考。

关键事实与外部链接

代码
USNA
合计市值
$19.4M
最大持有人
Richard Pzena
外部数据

数据来源· SEC EDGAR 13F 截至 2026-04-24

相关页面

订阅更新

每期精选 13F 异动与估值洞察,直达你的邮箱。